# Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

> **NCT04786964** · PHASE3 · TERMINATED · sponsor: **Checkpoint Therapeutics, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Non-squamous Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Cosibelimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DIETARY_SUPPLEMENT:** Folic acid 350-1000 μg
- **DIETARY_SUPPLEMENT:** Vitamin B12 1000 μg
- **DRUG:** Dexamethasone 4mg

## Key facts

- **NCT ID:** NCT04786964
- **Lead sponsor:** Checkpoint Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-08
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Regional political conflict
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04786964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04786964, "Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04786964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*